In the malignant glioma patients receiving the anti-SVN vaccine, the CD9+/GFAP+/SVN+ and CD9+/SVN+ exosomes were released into the circulation while their early reduction after anti-SVN immunotherapy was related to longer progression-free survival [64]. Here, CD9 is linked to malignant glioma.